Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CSL Behring announced that it is set to commence operations in its newly expanded facility now that the US Food & Drug Administration (FDA) has granted approval.
Subscribe to our email newsletter
The expansion significantly increases plasma processing and albumin production capacity in the Kankakee, Ill. facility.
The new facility will use the same state-of-the-art technology as CSL Behring’s long-standing manufacturing center of excellence in Bern, Switzerland. This is an important step towards a common fractionation process throughout CSL Behring’s global manufacturing network. The expansion is necessary due to the growing worldwide demand for CSL Behring’s immunoglobulins and albumin.
CSL Behring’s Executive Vice President Global Operations and Planning, Mary Sontrop, said the expansion in Kankakee is part of CSL Behring’s multi-site expansion plan, which includes the expansion of its manufacturing facilities in Broadmeadows, Australia; Bern, Switzerland; and Marburg, Germany.
"CSL Behring is committed to serving patients with rare diseases in all corners of the world," Sontrop said.
"In today’s competitive market, we continually explore the latest technology that’s available, and evaluate how it can make our operations and physical plant more efficient to meet patients’ growing needs. Increasing Kankakee’s ability to fractionate plasma and produce albumin and intermediate paste is an important step for our global operations."
Sontrop explained that the intermediate paste produced in Kankakee is sent to CSL Behring’s other manufacturing facilities where it is used to make therapies for the treatment of immune deficiencies, bleeding and other medical disorders.
Albumin is a plasma expander that quickly makes up for blood loss in accident victims, and that is also used to treat burn patients.